At a glance
- Originator Eisai Co Ltd
- Class Amides; Antineoplastics; Dipeptides; Piperidines
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 10 Nov 2009 Eisai has completed three phase I trials in Solid tumours in the US
- 09 Jul 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events, pharmacokinetics and Cancer therapeutic trials sections ,
- 03 Jul 2007 E 7974 is still in phase I trials for solid tumours in the US